Zobrazeno 1 - 10
of 268
pro vyhledávání: '"fviii inhibitors"'
Autor:
Massimo Morfini, Jacopo Agnelli Giacchiello, Erminia Baldacci, Christian Carulli, Giancarlo Castaman, Anna Chiara Giuffrida, Giuseppe Malcangi, Angiola Rocino, Sergio Siragusa, Ezio Zanon
Publikováno v:
Hematology Reports, Vol 15, Iss 2, Pp 384-397 (2023)
The Medical Directors of nine Italian Hemophilia Centers reviewed and discussed the key issues concerning the replacement therapy of hemophilia patients during a one-day consensus conference held in Rome one year ago. Particular attention was paid to
Externí odkaz:
https://doaj.org/article/d24dcae5a7a04163aca7e5a8789dc405
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Yung-Tsung Kao, Chih-Ching Yen, Hueng-Chuen Fan, Jen-Kun Chen, Ming-Shan Chen, Ying-Wei Lan, Shang-Hsun Yang, Chuan-Mu Chen
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 22, p 16411 (2023)
Hemophilia is a genetic disorder linked to the sex chromosomes, resulting in impaired blood clotting due to insufficient intrinsic coagulation factors. There are approximately one million individuals worldwide with hemophilia, with hemophilia A being
Externí odkaz:
https://doaj.org/article/e21d0f33d3a6413a9004653719435157
Autor:
Christian Lubich, Katharina Nora Steinitz, Brigitte Hoelbl, Thomas Prenninger, Pauline Maria van Helden, Markus Weiller, Birgit Maria Reipert
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Background and aimsHemophilia A is a severe bleeding disorder caused by the deficiency of functionally active coagulation factor VIII (FVIII). The induction of neutralizing anti-drug antibodies is a major complication in the treatment of hemophilia A
Externí odkaz:
https://doaj.org/article/1e39f338c08a413697c869e4dc98b02c
Autor:
Carmen Escuriola Ettingshausen, Vladimír Vdovin, Nadezhda Zozulya, Pavel Svirin, Tatiana Andreeva, Majda Benedik-Dolničar, Victor Jiménez-Yuste, Lidija Kitanovski, Silva Zupancic-Šalek, Anna Pavlova, Angelika Bátorová, Cesar Montaño Mejía, Gulnara Abdilova, Sigurd Knaub, Martina Jansen, Shannely Lowndes, Larisa Belyanskaya, Olaf Walter, Johannes Oldenburg
Publikováno v:
TH Open, Vol 06, Iss 02, Pp e124-e134 (2022)
Background Immune tolerance induction (ITI) with repeated factor VIII (FVIII) administration is the only strategy proven to eradicate inhibitors. The observational ITI study is evaluating ITI with a range of FVIII products. Methods This subgroup anal
Externí odkaz:
https://doaj.org/article/a52b126df9af4fd18ab2a85705afdb71
Autor:
Linari S, Castaman G
Publikováno v:
Therapeutics and Clinical Risk Management, Vol Volume 16, Pp 461-469 (2020)
Silvia Linari, Giancarlo Castaman Department of Oncology, Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, ItalyCorrespondence: Giancarlo CastamanDepartment of Oncology, Center for Bleeding Disorders and Coagulati
Externí odkaz:
https://doaj.org/article/9108241082084677a448b1e4b3d7bd2b
Autor:
Sandrine Delignat, Julie Rayes, Suryasarathi Dasgupta, Bagirath Gangadharan, Cécile V. Denis, Olivier D. Christophe, Jagadeesh Bayry, Srinivas V. Kaveri, Sébastien Lacroix-Desmazes
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
The development of an immune response against therapeutic factor VIII is the major complication in hemophilia A patients. Oligomannose carbohydrates at N239 and/or N2118 on factor VIII allow its binding to the macrophage mannose receptor expressed on
Externí odkaz:
https://doaj.org/article/56cbe631476a4dda8386f9a407c8d613
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Mathias, Mary, Abraham, Aby, Belletrutti, Mark, Carcao, Manuel, Carvalho, Manuela, Chambost, Hervé, Chan, Anthony, Dubey, Leonid, Ducore, Jonathan, Gattens, Michael, Gresele, Paolo, Gruel, Yves, Guillet, Benoit, Jiménez-Yuste, Victor, Kitanovski, Lidija, Klukowska, Anna, Lohade, Sunil, Mancuso, Maria Elisa, Oldenburg, Johannes, Pollio, Berardino, Sigaud, Marianne, Vilchevska, Kateryna, Wu, John, Jansen, Martina, Belyanskaya, Larisa, Walter, Olaf, Knaub, Sigurd, Neufeld, Ellis
Publikováno v:
European Journal of Haematology
European Journal of Haematology, 2023, ⟨10.1111/ejh.14040⟩
European Journal of Haematology, 2023, ⟨10.1111/ejh.14040⟩
Introduction: Simoctocog alfa (Nuwiq®) is a 4th generation recombinant FVIII with proven efficacy for the prevention and treatment of bleeding episodes (BEs) in previously treated patients with severe haemophilia A. The NuProtect study assessed the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::427bfebdcf4559e4b51cdc4bcc8faee0
https://univ-rennes.hal.science/hal-04165547
https://univ-rennes.hal.science/hal-04165547
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.